AstraZeneca PLC
LSE:AZN
AstraZeneca PLC
LSE:AZN
Price:
13 948
GBX
1.87%
Market Closed
Market Cap:
£216.3B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
2022 was a year of continued strong company performance and execution of our long-term growth strategy. Our pioneering science was evident across all therapy areas, and I'm really proud of what we were able to achieve for patients around the world.
In 2023, we expect to see another year of double-digit revenue growth, excluding our COVID-19 medicines as we bring more medicines to more patients than ever before. And we plan to initiate more than 30 Phase III trials this year, 10 of which have blockbuster potential. And with our continued progress, we are on track to deliver industry-leading growth for 2025 and beyond and deliver at least 15 new medicines before the end of the decade.
My thanks to all of our team for the part they played in achieving our strong results and for continuing to unlock the power of what science can do for people, society and the planet.